BNGO BIONANO GENOMICS INC

Bionano Genomics to Host Strategy Day on February 2, 2023 in New York City

Bionano Genomics to Host Strategy Day on February 2, 2023 in New York City

SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host its first-ever Strategy Day on Thursday, February 2nd, 2023, at the Nasdaq MarketSite in New York City, starting at 1:30 PM ET. The event will include presentations from members of the company's leadership team and panel discussions featuring key opinion leaders in basic and clinical research areas including cancer, genetic disorders and cell bioprocessing. Bionano panel members will also participate in a Q&A discussion with the audience.

The event will include a live webcast which will be archived and available for replay after the event. Please visit the "Investors" section of the company website at to register for the webcast and for additional information on the event.

About Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.

For more information, visit ,  or 

CONTACTS



Company Contact:

Erik Holmlin, CEO

Bionano Genomics, Inc.

+1 (858) 888-7610

Investor Relations:

Amy Conrad

Juniper Point

+1 (858) 366-3243



EN
06/01/2023

Underlying

BNGOBIONANO GENOMICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIONANO GENOMICS INC

 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Bionano to Present at the H.C. Wainwright 27th Annual Global Investmen...

Bionano to Present at the H.C. Wainwright 27th Annual Global Investment Conference SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8th, 2025. Conference & Webcast Details Date:September 8, 2025Time:3:00 p.m. to 3:30 p.m. ETPresenter:Erik Holmlin, PhD, CEO of BionanoWebcast:   A replay / recording of the session will be available following the conference through ...

August 25, 2025 1 EN
 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Bionano Reports Second Quarter 2025 Results and Highlights Recent Busi...

Bionano Reports Second Quarter 2025 Results and Highlights Recent Business Progress Conference call today, August 14, 2025, at 4:30 PM ET SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2025. “We continued to execute on our new strategy of focusing on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit in the second quarter. These routine users are increasingly leveraging our OGM systems and software a...

August 14, 2025 1 EN
 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Bionano Announces Publication Showing Utility of Optical Genome Mappin...

Bionano Announces Publication Showing Utility of Optical Genome Mapping in Clinical Research of Infant & Toddler T-ALL SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from a team led by Manon Delafoy from the Institut Necker Enfants Malades (INEM) and colleagues from multiple French pediatric hematology centers showing how optical genome mapping (OGM) can be used to detect oncogenic structural variants (SVs) in clinical research of infant and toddler T-cell acute lymphoblastic leukemia (T-ALL). The publication...

August 7, 2025 1 EN
 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Bionano to Present at the Canaccord Genuity 45th Annual Growth Confere...

Bionano to Present at the Canaccord Genuity 45th Annual Growth Conference SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025. Conference & Webcast Details Date:August 13, 2025Time:3:00 p.m. to 3:25 p.m. ETPresenter:Erik Holmlin, PhD, CEO of BionanoWebcast: A replay / recording of the session will be available following the conference through the Bionano website at  for at...

August 6, 2025 1 EN
 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Bionano Announces Upgrades to its Software and Compute Platforms to Ma...

Bionano Announces Upgrades to its Software and Compute Platforms to Make Analysis of OGM, Microarray and NGS Data Easier, Faster and More Accurate VIA™ 7.2 transforms the workflow for optical genome mapping (OGM) data analysis with AI in constitutional genetic disorders VIA 7.2 supercharges the OGM heme workflow by allowing AI to utilize a lab’s historical results to speed future interpretations VIA 7.2 extends significance associated with phenotype (SAP) scoring to OGM data for the first time and uses that score to help streamline interpretation decisions for OGM variantsVIA 7.2 includes s...

August 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch